表紙
市場調査レポート

癌免疫療法のための薬剤開発と免疫チェックポイント薬:パイプラインの最新情報

Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update

発行 BioSeeker Group AB 商品コード 317979
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
癌免疫療法のための薬剤開発と免疫チェックポイント薬:パイプラインの最新情報 Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update
出版日: 2016年08月04日 ページ情報: 英文
概要

免疫チェックポイント阻害剤には現在、Yervoy (ipilimumab)、Keytruda (Pembrolizumab)、Opdivo (nivolumab)の3種の承認薬があります。Bristol-Myers SquibbのYervoy(CTLA4標的抗体)は2011年に切除不能または転移性メラノーマの患者向けの薬剤として初めて承認されました。2013年における世界の売上高は、Yervoy単体で10億ドルに近い規模(9億6,000万)を記録しています。翌2014年には、小野薬品工業のOpdivo、続いてMerck & CoのKeytrudaが新たに承認されました。KeytrudaおよびOpdivoはともにPD-1阻害剤であり、黒色腫の治療薬として承認されています。癌の免疫チェックポイントを標的とする薬剤の開発は比較的多く実行されていますが、それとは別に、業界では併用療法に関連する多くの契約も結ばれています。現在、309件の開発プロジェクト下で59の事業者とそのパートナー企業が109種の免疫チェックポイント薬の開発を行っています。

当レポートでは、免疫チェックポイント薬の最新の開発動向について調査し、開発事業者、標的、開発段階、適応症、生体構造、作用機序などを詳細にわたってまとめています。

開発事業者

薬剤名および異名

  • 商標名
  • ジェネリック薬
  • コードネーム

開発段階

  • 上市済み
  • 登録前
  • 第3相
  • 第2相
  • 第1相
  • 前臨床
  • 中断
  • 中止

適応症

標的

突然変異

  • COSMIC (Catalogue Of Somatic Mutations In Cancer)

生体構造

標的発現プロファイル

経路参照

  • BioCarta
  • KEGG
  • NCI-Nature
  • NetPath

機序

化合物

薬剤プロファイル

  • 主となる事業者とパートナー事業者
  • 標的および標的の分子機能
  • 標的の部位
  • 突然変異
  • 生体構造
  • 標的経路
  • 作用機序
  • 開発プロジェクト
  • 薬剤解説
  • 化合物データ
  • 特許データ
  • 第4相データ
  • 第3相データ
  • 第2相データ
  • 第1相データ
  • 第0相データ
  • 臨床前データ
  • 創薬データ

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BSG18518

BioSeeker's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. BioSeeker's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively.

There are currently four approved immune check point inhibitors, namely Yervoy (ipilimumab), Opdivo (nivolumab), Keytruda (pembrolizumab) and Tecentriq (atezolizumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co's Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were first approved for treatment of melanoma. In 2016 Roche's PD-L1 inhibitor Tecentriq was granted an accelerated approval by the US FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma. Collectively, immune checkpoint inhibitors are currently approved for the treatment of five different cancer types: bladder cancer, Hodkin's lymphoma, melanoma, non-small cell lung cancer and renal cancer. The world-wide Q2 2016 sales for these drugs were; Yervoy (241m USD), Opdivo (840m USD), Keytruda (314m USD) and Tecentriq (19m CHF).

There are today 120 companies plus partners developing 227 immune checkpoints drugs in 835 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Targeting Immune Checkpoints In Cancer Immunotherapy Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 71 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 66 out of the 66 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 23 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

  • Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.

Table of Contents

Drug Pipeline Update at a Glance

Investigators

  • Includes more than 120 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
  • Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms

  • Lists commercial, generic and code names for drugs.

Developmental stage

  • This Drug Pipeline Update contains 227 immune checkpoints drugs in development, which have a total of 835 developmental projects in cancer. In addition there are suspended and ceased drugs.
  • Pipeline Breakdown According to Number of Drugs
  • Marketed# 4
  • Pre-registration# 2
  • Phase III# 11
  • Phase II# 36
  • Phase I# 86
  • Preclinical# 103
  • No Data# 1
  • Suspended# 4
  • Ceased# 19
  • Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.

Indications

  • Included immune checkpoints drugs are also in development for 131 other indications, where of 115 are different cancer indications.
  • Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.

Targets

  • Mutations
  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 66 out of the 66 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
  • Biological Structures
  • The identity of available biological structures on 50 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 407 structures available today among drug targets.
  • Identified drugs are linked to more than 71 different targets, divided into 23 classifications of molecular function:
  • Antigen binding
  • Carboxypeptidase activity
  • Catalytic activity
  • Cell adhesion molecule activity
  • Cysteine-type peptidase activity
  • Cytokine activity
  • Defense/immunity protein activity
  • G-protein coupled receptor activity
  • Growth factor activity
  • Heat shock protein activity
  • Molecular function unknown
  • Oxidoreductase activity
  • Receptor activity
  • Receptor binding
  • Receptor signaling complex scaffold activity
  • RNA-directed DNA polymerase activity
  • Serine-type peptidase activity
  • Structural constituent of cytoskeleton
  • T cell receptor activity
  • T cell receptor binding
  • Transcription regulator activity
  • Transmembrane receptor activity
  • Transmembrane receptor protein tyrosine kinase activity
  • Sub-Cellular Localization
  • Identified targets are categorized into 14 different primary and alternate sub-cellular localizations:
  • Cell surface
  • Clathrin-coated vesicle
  • Cytoplasm
  • Endoplasmic reticulum
  • Endosome
  • Extracellular
  • Golgi apparatus
  • Kinetochore
  • Lysosome
  • Mitochondrion
  • Nucleolus
  • Nucleus
  • Plasma membrane
  • Vesicle
  • Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.

Target Expression Profile

  • Direct links are provided from inside the application to 85 protein expression profiles of 55 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Pathway Referals

  • Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
  • BioCarta# 77 Pathways
  • KEGG# 103 Pathways
  • NCI-Nature# 81 Pathways
  • NetPath# 19 Pathways
  • Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.

Mechanism

  • In total there are different drug mechanism of action represented in this Drug Pipeline Update.
  • Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.

Compound

  • Identified drug compounds are described by:
  • Compound type, Chemical name, CAS Number and molecular weight
  • Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.

Drug Profile

  • Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
  • Drug Name & Synonyms
  • Presentation of drug name and synonyms

Principal Company & Partners

  • Presentation of principal company and partners

Target and Molecular Function of Target

  • Described target(s) is/are presented with:
  • Official Gene Symbol - Chromosome Location - Gene & Protein Name - Molecular Function

Target Localization

  • Described target(s) is/are presented with primary and alternate localizations.
  • Target Expression Profiles
  • Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
  • 48 different normal tissue types
  • 20 different types of cancer
  • 47 cell lines
  • 12 samples of primary blood cells

Mutation

  • All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
  • Biological Structures
  • The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.

Targeted Pathways

  • Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.

Mechanism

  • Drug mechanism of action

Developmental Projects

  • Summary field of developmental projects for the drug, including indication, developmental stage and status.
  • Example:
  • Cancer, myeloma - Phase II Clinical Trial - Active
  • Cancer, prostate - Phase III Clinical Trial - Ceased

Drug Description

  • Short introduction to drug

Compound Data

  • Compound type, Chemical name, CAS Number and molecular weight

Patent Data

  • Available patent information related to the drug is presented here.

Fillings and Approvals

  • Approvals and submissions
  • Analyst comments
  • Deals & Licensing
  • Collaborations and deals
  • Availability for licensing

Phase IV Data

  • Available Phase IV development data, developmental history and scientific data.

Phase III Data

  • Available Phase III development data, developmental history and scientific data.

Phase II Data

  • Available Phase II development data, developmental history and scientific data.

Phase I Data

  • Available Phase I development data, developmental history and scientific data.

Phase 0 Data

  • Available Phase 0 development data, developmental history and scientific data.

Preclinical Data

  • Available preclinical development data, developmental history and scientific data.

Discovery Data

  • Available discovery development data, developmental history and scientific data.

Application Features

  • Search, Find and Filter Panel with Initial Result Presentation
  • With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
  • The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
  • Direct linkage from inside the application to related internet resources
  • Drug data is linked to search engines like Google and PubMed
  • Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
  • Direct links to company web pages of companies

Dynamic Report Generator

  • Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.

System Requirements

  • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
  • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
  • Internet access (to access related internet resources)
Back to Top